; and (2) by adding at the end the following new paragraph: (2) Preventing potential drug shortages (A) In general In the case of a drug or biological described in subparagraph (B), the Secretary may use the wholesale acquisition cost (or other reasonable measure of a drug or biological price) instead of the manufacturer’s average sales price for quarters beginning on or after the date on which the Secretary determines the drug or biological is described in such subparagraph and for subsequent quarters until the end of the quarter in which such drug or biological is removed from the drug shortage list under section 506E of the Federal Food, Drug, and Cosmetic Act, or in the case of a drug or biological described in subparagraph (B)(ii)(II), the date on which the Secretary determines the manufacturing capacity or the number of manufacturers of such drug or biological is sufficient to prevent a potential shortage of the drug or biological. (B) Drug or biological described For purposes of subparagraph (A), a drug or biological described in this subparagraph is a drug or biological— (i) that is life-supporting, life-sustaining, or intended for use in the prevention or treatment of a debilitating disease or condition (as those terms are defined for purposes of section 506C of the Federal Food, Drug, and Cosmetic Act and is subject to the reporting requirements under section 506C(b) of such Act), including any such drug or biological that is used in emergency medical care or during surgery; and (ii) (I) that is listed on the drug and biological shortage list maintained by the Food and Drug Administration pursuant to section 506E of the Federal Food, Drug, and Cosmetic Act, and for which the manufacturer of such drug or biological notifies the Secretary of a permanent discontinuance or an interruption that is likely to lead to a meaningful disruption in the manufacturer’s supply of that drug or biological pursuant to section 506C(b)(1) of such Act